Literature DB >> 18456692

Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study.

F J K O'Callaghan1, C N Martyn, S Renowden, M Noakes, D Presdee, J P Osborne.   

Abstract

OBJECTIVES: (1) In a population-based study of tuberous sclerosis (TSC), to identify the number of patients presenting with symptomatic giant cell astrocytomas (GCAs); (2) within a subset of this population, to identify the number who would be diagnosed with GCAs on predetermined radiological criteria.
METHODS: Patients with TSC in Wessex (a geographical region of England) were identified, and their medical history determined. A subset were invited to have a cranial MRI if they did not have a history of a symptomatic GCA and if they were likely to tolerate cranial imaging without a general anaesthetic. Scans were performed according to a standard protocol on a single scanner and were reported blindly by a neuroradiologist.
RESULTS: 179 people were identified with TSC. Ten of these had a history of treatment for a symptomatic GCA. Forty-one of the remainder had a cranial MRI. Thirty-nine of these had subependymal nodules, of whom 24 (59%) had at least one (maximum 11) that showed enhancement with gadolinium. In seven (17%), the lesion was >1 cm, and all of these lesions showed gadolinium enhancement.
CONCLUSIONS: In this study, the proportion of patients with TSC who had a history of symptomatic GCA was 5.6%. In the subset without such a history, who underwent imaging, the number diagnosed as having a GCA on radiological criteria was much higher (59% gadolinium enhancement and 17% >1 cm in size). Screening for GCAs (performing scans on asymptomatic patients with TSC) would therefore identify large numbers of patients who had not presented with symptoms. This finding leads us to recommend that screening should not be undertaken.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456692     DOI: 10.1136/adc.2007.125880

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  12 in total

1.  Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients.

Authors:  Flavio Giordano; Carla Moscheo; Matteo Lenge; Roberto Biagiotti; Francesco Mari; Iacopo Sardi; Anna Maria Buccoliero; Lorenzo Mongardi; Eleonora Aronica; Renzo Guerrini; Lorenzo Genitori
Journal:  Childs Nerv Syst       Date:  2019-12-18       Impact factor: 1.475

Review 2.  Neurosurgical treatment of tuberous sclerosis complex lesions.

Authors:  Ignacio Pascual-Castroviejo
Journal:  Childs Nerv Syst       Date:  2011-05-24       Impact factor: 1.475

3.  Subependymal nodules and giant cell tumours in tuberous sclerosis complex patients: prevalence on MRI in relation to gene mutation.

Authors:  Caterina Michelozzi; Giovanni Di Leo; Federica Galli; Fabiane Silva Barbosa; Francesca Labriola; Francesco Sardanelli; Gianpaolo Cornalba
Journal:  Childs Nerv Syst       Date:  2012-08-31       Impact factor: 1.475

Review 4.  Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective.

Authors:  Moncef Berhouma
Journal:  World J Pediatr       Date:  2010-05-21       Impact factor: 2.764

Review 5.  The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective.

Authors:  Romina Moavero; Mariangela Pinci; Roberta Bombardieri; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2011-02-09       Impact factor: 1.475

6.  Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex.

Authors:  Àlex Rovira; María Luz Ruiz-Falcó; Elena García-Esparza; Eduardo López-Laso; Alfons Macaya; Ignacio Málaga; Élida Vázquez; Josefina Vicente
Journal:  J Neurooncol       Date:  2014-04-27       Impact factor: 4.130

Review 7.  The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.

Authors:  Sam Amin; Andrew Lux; Finbar O'Callaghan
Journal:  Br J Clin Pharmacol       Date:  2018-11-08       Impact factor: 4.335

8.  Clinically relevant imaging in tuberous sclerosis.

Authors:  Rupa Radhakrishnan; Sadhna Verma
Journal:  J Clin Imaging Sci       Date:  2011-07-27

Review 9.  Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

Authors:  Samy L Habib; Noor Y Al-Obaidi; Maciej Nowacki; Katarzyna Pietkun; Barbara Zegarska; Tomasz Kloskowski; Wojciech Zegarski; Tomasz Drewa; Edward A Medina; Zhenze Zhao; Sitai Liang
Journal:  J Cancer       Date:  2016-07-21       Impact factor: 4.207

10.  Clinical management of tuberous sclerosis complex over the lifetime of a patient.

Authors:  Michael Frost; John Hulbert
Journal:  Pediatric Health Med Ther       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.